{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:42:12Z","timestamp":1780051332977,"version":"3.53.1"},"reference-count":59,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polish Lung Cancer Study Group"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Molecular testing is recommended in patients with metastatic non-small cell lung cancer (NSCLC), but the extent of its use in Poland is unknown. The aim of the POL-MOL study was to investigate the frequency of using molecular testing in Polish patients with NSCLC. The invited Polish oncologists completed two questionnaires, and data for 1001 patients undergoing systemic treatment for NSCLC were collected. The use of molecular tests for the following genetic mutations was recorded: EGFR (del19, sub21), EGFR (other than del19\/sub21), EGFR T790M, ALK (expression and rearrangement), RET, NTRK, ROS1, BRAF, HER2, and MET, as well as for immunochemical assessment of programmed cell death ligand 1 (PD-L1). Thanks to the weighting procedure, the results are representative of the population of Polish patients treated for NSCLC. Molecular tests were applied in 78% of patients with NSCL, 70% of patients with NSCLC not otherwise specified, and in 12% of patients with squamous cell carcinoma of the lung. The frequency of application increased with disease stage in all groups. In patients with squamous cell carcinoma, approximately 30% of tests for EGFR, ALK, and RET mutations were positive, which confirms the importance of testing at least a preselected subgroup of patients.<\/jats:p>","DOI":"10.3390\/ijms252111354","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:53:43Z","timestamp":1729583623000},"page":"11354","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The Detailed Analysis of Polish Patients with Non-Small Cell Lung Cancer Through Insights from Molecular Testing (POL-MOL Study)"],"prefix":"10.3390","volume":"25","author":[{"given":"Dariusz M.","family":"Kowalski","sequence":"first","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Zaborowska-Szmit","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Bryl","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"},{"name":"Centre of Pulmonology and Thoracic Surgery, 60-569 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Byszek","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3931-8636","authenticated-orcid":false,"given":"Dariusz Adam","family":"Dziedzic","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"},{"name":"Department of Thoracic Surgery, National Institute of Tuberculosis and Pulmonary Disease, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ja\u015bkiewicz","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Langfort","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"},{"name":"Department of Pathology, National Institute of Tuberculosis and Pulmonary Disease, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[{"name":"Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"},{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Or\u0142owski","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"},{"name":"Department of Thoracic Surgery, National Institute of Tuberculosis and Pulmonary Disease, 01-138 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodryg","family":"Ramlau","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"},{"name":"Institute of Oncology, Poznan University of Medical Sciences, 60-514 Pozna\u0144, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Szmit","sequence":"additional","affiliation":[{"name":"Polish Lung Cancer Study Group, 01-138 Warsaw, Poland"},{"name":"Department of Cardio-Oncology, Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland"},{"name":"Department of Cancer Diagnostics and Cardio-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.gendis.2022.07.023","article-title":"Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics","volume":"10","author":"Padinharayil","year":"2022","journal-title":"Genes Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5603\/OCP.2022.0052","article-title":"Delays in the diagnosis of lung cancer patients in Poland","volume":"9","author":"Nalewaj","year":"2023","journal-title":"Oncol. Clin. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","unstructured":"American Cancer Society (2018). Global Cancer Facts & Figures, American Cancer Society. [4th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jtho.2020.03.035","article-title":"Lung Cancer in Poland","volume":"15","author":"Adamek","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"ref_7","unstructured":"European Union 2021 (2024, September 13). ECIS\u2014European Cancer Information System. Available online: https:\/\/ecis.jrc.ec.europa.eu."},{"key":"ref_8","unstructured":"Ferlay, J., Laversanne, M., Ervik, M., Lam, F., Colombet, M., Mery, L., Pi\u00f1eros, M., Znaor, A., Soerjomataram, I., and Bray, F. (2020). Global Cancer Observatory: Cancer Tomorrow, International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/tomorrow."},{"key":"ref_9","unstructured":"Didkowska, J., Wojciechowska, U., and \u015aliwczy\u0144ski, A. (2019). Report on the Stages of Advancement, Treatment, and Survival of Lung Cancer Patients Registered with the National Cancer Registry (KRN) from 2014 to 2016, Maria Sk\u0142odowska-Curie National Research Institute of Oncology. National Cancer Registry."},{"key":"ref_10","unstructured":"Wild, C.P., Weiderpass, E., and Stewart, B.W. (2020). World Cancer Report: Cancer Research for Cancer Prevention, International Agency for Research on Cancer, WHO."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Ryska, A., Berzinec, P., Brcic, L., Cufer, T., Dziadziuszko, R., Gottfried, M., Kovalszky, I., Olszewski, W., Oz, B., and Plank, L. (2018). NSCLC molecular testing in Central and Eastern European countries. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4023-4"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","unstructured":"(2024, September 13). American Cancer Society: About Non-Small Cell Lung Cancer. Available online: https:\/\/www.cancer.org\/content\/dam\/CRC\/PDF\/Public\/8703.00.pdf."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_16","first-page":"122","article-title":"Personalised medicine in lung cancer","volume":"71","author":"Gil","year":"2021","journal-title":"Nowotw. J. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/annonc\/mdu145","article-title":"Second ESMO consensus conference on lung cancer: Pathology and molecular biomarkers for non-small-cell lung cancer","volume":"25","author":"Kerr","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/JTO.0b013e318206a221","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society international multidisciplinary classification of lung Adenocarcinoma","volume":"6","author":"Travis","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.lungcan.2013.07.025","article-title":"Genetic alterations defining NSCLC subtypes and their therapeutic implications","volume":"82","author":"Pikor","year":"2013","journal-title":"Lung Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Pujol, N., Heeke, S., Bontoux, C., Boutros, J., Ili\u00e9, M., Hofman, V., Marquette, C.H., Hofman, P., and Benzaquen, J. (2022). Molecular profiling in non-squamous non-small cell lung carcinoma: Towards a switch to next-generation sequencing reflex testing. J. Pers. Med., 12.","DOI":"10.3390\/jpm12101684"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1002\/onco.13586","article-title":"Navigating diagnostic and treatment decisions in non-small cell lung cancer: Expert commentary on the multidisciplinary team approach","volume":"26","author":"Popat","year":"2021","journal-title":"Oncologist"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"ref_23","first-page":"301","article-title":"Minimal requirements for the molecular testing of lung cancer","volume":"3","author":"Popper","year":"2014","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"610","DOI":"10.6004\/jnccn.2021.5020","article-title":"Non\u2013small cell lung cancer: Recommendations for biomarker testing and treatment","volume":"19","author":"Aisner","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1093\/annonc\/mdu123","article-title":"2nd ESMO consensus conference on lung cancer: Non-small-cell lung cancer first-line\/second and further lines of treatment in advanced disease","volume":"25","author":"Besse","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Smolle, E., and Pichler, M. (2019). Non-smoking-associated lung cancer: A distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition. Cancers, 11.","DOI":"10.3390\/cancers11020204"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0031-1272866","article-title":"Pathological diagnosis and classification of lung cancer in small biopsies and cytology: Strategic management of tissue for molecular testing","volume":"32","author":"Travis","year":"2011","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1164\/rccm.201903-0493OC","article-title":"Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis","volume":"200","author":"Walsh","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/tlcr.2019.04.14","article-title":"Molecular testing strategies in non-small cell lung cancer: Optimizing the diagnostic journey","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/cncy.22318","article-title":"Predictive molecular pathology in non-small cell lung cancer in France: The past, the present and the perspectives","volume":"128","author":"Hofman","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN Guidelines Insights: Non\u2013Small Cell Lung Cancer, Version 2.2021: Featured Updates to the NCCN Guidelines","volume":"19","author":"Ettinger","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JTO.0000000000000516","article-title":"LCMC Investigators. Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience","volume":"10","author":"Sholl","year":"2015","journal-title":"J. Thorac. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/thoraxjnl-2014-206677","article-title":"Diagnostic procedures for non-small-cell lung cancer (NSCLC): Recommendations of the European Expert Group","volume":"71","author":"Dietel","year":"2016","journal-title":"Thorax"},{"key":"ref_35","unstructured":"P\u0105zik, M., Mirowski, M., and Balcerczak, E. (2022). Current Approach to Non-Small Cell Lung Cancer Diagnosis and Treatment\u2014A Short Review, Wydawnictwo Uniwersytetu Medycznego w \u0141odzi."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","article-title":"Molecular Testing Guideline for the Selection of Patients with Lung Cancer for Treatment with Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists\/International Association for the Study of Lung Cancer\/Association for Molecular Pathology Clinical Practice Guideline Update","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/JTO.0b013e318290868f","article-title":"Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology","volume":"8","author":"Lindeman","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2021.09.003","article-title":"Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges","volume":"162","author":"Aggarwal","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_40","first-page":"431","article-title":"The detection of EGFR mutations in patients with non-small cell lung cancer in selected molecular diagnostics centers in Poland","volume":"9","author":"Krawczyk","year":"2012","journal-title":"Kardiochir. Torakochirurgia Pol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Trembecki, \u0141., Sztuder, A., Pawlak, I., Matkowski, R., and Maciejczyk, A. (2021). Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08994-z"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2017.04.004","article-title":"Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities","volume":"18","author":"Gutierrez","year":"2017","journal-title":"Clin. Lung Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/intqhc\/mzy027","article-title":"Quality of care and variability in lung cancer management across Belgian hospitals: A population-based study using routinely available data","volume":"30","author":"Vrijens","year":"2018","journal-title":"Int. J. Qual. Health Care"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lee, D.H., Tsao, M.S., Kambartel, K.O., Isobe, H., Huang, M.S., Barrios, C.H., Khattak, A., de Marinis, F., Kothari, S., and de Castro, J. (2018). Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202865"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e12721","DOI":"10.1111\/ecc.12721","article-title":"Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices","volume":"26","author":"Ess","year":"2017","journal-title":"Eur. J. Cancer Care"},{"key":"ref_47","first-page":"3979","article-title":"Patients with Non-small Cell Lung Cancer Analyzed for EGFR: Adherence to Guidelines, Prevalence and Outcome","volume":"35","author":"Sandelin","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2020.10.012","article-title":"CRISP Registry Group: Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)","volume":"152","author":"Griesinger","year":"2021","journal-title":"Lung Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e901","DOI":"10.1016\/j.cllc.2021.05.006","article-title":"Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists","volume":"22","author":"Waterhouse","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"ref_51","unstructured":"Gill, J., Fontrier, A.-M., Miracolo, A., and Kanavos, P. (2020). Access to Personalised Oncology in Europe, London School of Economics."},{"key":"ref_52","unstructured":"(2024, September 13). Reimbursement Announcement of the Polish Ministry of Health no. 67 (1 January 2023), Available online: https:\/\/www.gov.pl\/attachment\/420adc35-6fb1-4060-8c7a-f215886f7a23."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cam4.4459","article-title":"Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: Results of a survey of U.S. oncologists","volume":"11","author":"Mileham","year":"2022","journal-title":"Cancer Med."},{"key":"ref_54","unstructured":"Association of Community Cancer Centers Operational Pathways for Biomarker Testing in NSCLC (2024, September 13). Environmental Scan. Available online: https:\/\/www.accc-cancer.org\/docs\/projects\/operational-pathways-in-nsclc\/accc-operational-pathways_final-(2).pdf."},{"key":"ref_55","first-page":"4","article-title":"Molecular Diagnostic Testing in Non-Small Cell Lung Cancer","volume":"10","author":"Naidoo","year":"2014","journal-title":"Am. J. Hematol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., and Zhou, H. (2022). Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives. Cells, 11.","DOI":"10.3390\/cells11203200"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/13696998.2022.2053403","article-title":"Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer","volume":"25","author":"Vanderpoel","year":"2022","journal-title":"J. Med. Econ."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fon-2021-1040","article-title":"Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: A literature review","volume":"18","author":"Zheng","year":"2022","journal-title":"Future Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1007\/s12094-022-03046-9","article-title":"New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology","volume":"25","author":"Isla","year":"2023","journal-title":"Clin. Transl. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11354\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:17:47Z","timestamp":1760113067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/21\/11354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":59,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["ijms252111354"],"URL":"https:\/\/doi.org\/10.3390\/ijms252111354","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}